Markets:

Overview

News

Currencies

International

Treasuries

Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

5.050 +0.030 (+0.60%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Unicycive Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb

March 06, 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers

March 03, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers

March 03, 2023

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers

Via News Direct

The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers ↗

March 02, 2023

Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and...

Via Benzinga

Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

February 27, 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Unicycive: The Company Developing Key Kidney Therapies

February 17, 2023

by\nJohnny Rice, Benzinga Contributor

Via News Direct

Unicycive: The Company Developing Key Kidney Therapies

February 17, 2023

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.

Via TheNewswire.com

Unicycive: The Company Developing Key Kidney Therapies ↗

February 16, 2023

Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 07, 2023

Via Benzinga

Unicycive: This Biotech Company Receives Promising Results From New Trial

February 06, 2023

Unicycive: This Biotech Company Receives Promising Results From New Trial

Via News Direct

Unicycive: This Biotech Company Receives Promising Results From New Trial ↗

February 03, 2023

Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the...

Via Benzinga

Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea

February 02, 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 26, 2023

Via Benzinga

Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings

January 23, 2023

Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 06, 2023

Via Benzinga

Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

January 05, 2023

Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectively

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket ↗

January 03, 2023

Gainers

Via Benzinga

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

December 29, 2022

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗

December 30, 2022

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 29, 2022

Via Benzinga

Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket ↗

December 29, 2022

Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the...

Via Benzinga

Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher ↗

December 28, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday.

Via Benzinga

Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session ↗

December 28, 2022

Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 28, 2022

Via Benzinga

Dow Tumbles 150 Points; Crude Oil Falls Sharply ↗

December 28, 2022

U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday.

Via Benzinga

Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study ↗

December 28, 2022

Via Benzinga

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

December 28, 2022

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

December 22, 2022

Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023

From Unicycive Therapeutics, Inc.

Via GlobeNewswire

Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

December 09, 2022

Via ACCESSWIRE

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.